Pancreatic Cancer Global Clinical Trials Review, H1, 2018

Published : Apr-2018

No. of Pages : 1460

order by fax Inquire before Buying request discount

Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Report Guidance 5
GlobalData Clinical Trials Report Coverage 6
Clinical Trials by Region 7
Clinical Trials and Average Enrollment by Country 8
Top Five Countries Contributing to Clinical Trials in Asia-Pacific 10
Top Five Countries Contributing to Clinical Trials in Europe 11
Top Countries Contributing to Clinical Trials in North America 12
Top Five Countries Contributing to Clinical Trials in Middle East and Africa 13
Top Five Countries Contributing to Clinical Trials in Central and South America 14
Clinical Trials by G7 Countries: Proportion of Pancreatic Cancer to Oncology Clinical Trials 15
Clinical Trials by Phase in G7 Countries 16
Clinical Trials in G7 Countries by Trial Status 17
Clinical Trials by E7 Countries: Proportion of Pancreatic Cancer to Oncology Clinical Trials 18
Clinical Trials by Phase in E7 Countries 19
Clinical Trials in E7 Countries by Trial Status 20
Clinical Trials by Phase 21
In Progress Trials by Phase 22
Clinical Trials by Trial Status 23
Clinical Trials by End Point Status 24
Subjects Recruited Over a Period of Time 25
Clinical Trials by Sponsor Type 26
Prominent Sponsors 27
Top Companies Participating in Pancreatic Cancer Therapeutics Clinical Trials 28
Prominent Drugs 29
Latest Clinical Trials News on Pancreatic Cancer 30
Apr 18, 2018: BerGenBio: Promising data highlighting selective AXL inhibitor bemcentinib's potential to improve efficacy of checkpoint inhibitors presented at AACR 30
Apr 18, 2018: MabVax Therapeutics Antibody Program Results Featured in Three Presentations at 2018 American Association for Cancer Research (AACR) Annual Meeting 30
Apr 17, 2018: PharmaCyte Biotech Successfully Completes Multiple Course Ifosfamide Study 31
Apr 17, 2018: BERG Announces Data Presentations at AACR 2018 Validating Novel Prostate Cancer Biomarkers and Clinical Activity of BPM 31510 Across Several Metabolic Cancer Types 31
Apr 16, 2018: Syndax to Present on Entinostat at the 2018 American Association for Cancer Research Annual Meeting 32
Apr 16, 2018: Bioatla Announces FDA Clearance Of Investigational New Drug Application For CAB-ROR2-ADC Therapeutic 32
Apr 13, 2018: TyrNovo to Present at 2018 Annual Meeting of the American Association for Cancer Research 33
Apr 12, 2018: TCR2 Therapeutics to Present New Preclinical Data at the American Association for Cancer Research (AACR) 2018 Annual Meeting 33
Apr 12, 2018: AbGenomics Invited to 6th Annual Biologics World Taiwan, Dr. Shih-Yao Lin Speaks 33
Apr 09, 2018: Merrimack to Present Preclinical Data at the 2018 American Association for Cancer Research Annual Meeting 34
Apr 04, 2018: BERG Announces the Dosing of First UK Patient in Phase II Combination Trial of BPM 31510 and Gemcitabine for Patients with Pancreatic Cancer 34
Apr 02, 2018: PharmaCyte Ships Clinical Trial Cells to Austrianova for Encapsulation 34
Mar 26, 2018: Preclinical Data Showing Synergy of Biothera Pharmaceuticals' Imprime PGG and a CD40 Agonist in a Pancreatic Cancer Model Presented at Keystone Symposia 35
Mar 26, 2018: ARMO BioSciences Announces Positive Outcome of First Interim Analysis in SEQUOIA Phase 3 Pancreatic Cancer Study 35
Mar 19, 2018: Karyopharm to Present Preclinical Data on KPT-9274 at the American Association for Cancer Research 2018 Annual Meeting 36
Mar 16, 2018: "Recombinant ANTI-EpCAM And ANTI-CD3 Human-Mouse Chimeric Bispecific Antibody For Injection" Was Granted Drug Clinical Trial Approval 36
Mar 15, 2018: MabVax Therapeutics to present interim results from the Phase 1 clinical trial of MVT-1075 36
Mar 14, 2018: FDA Acceptance of IND for Tyme to Begin Phase II Trial in Pancreatic Cancer 37
Mar 08, 2018: TyrNovo to Present at BIO-Europe Spring 2018 Conference 37
Mar 05, 2018: Sorrento Therapeutics Autologous Anti-CEA CAR-T Cell Therapy for Liver Metastases Demonstrates Therapeutic Activity in Stage IV Pancreas Cancer in a Phase 1b HITM-SURE Trial (NCT02850536) 37
Mar 01, 2018: Fibrogen Granted Fast Track Designation by U.S. FDA for Pamrevlumab Treatment of Patients with Locally Advanced Unresectable Pancreatic Cancer 38
Feb 28, 2018: MabVax Therapeutics Reports Positive Safety Results from Initial Cohort of MVT-1075 Radioimmunotherapy Phase 1 Trial for the Treatment of Pancreatic, Colon and Lung Cancers 38
Feb 28, 2018: PharmaCyte Discusses Phase 2b Clinical Trial in Pancreatic Cancer 39
Feb 12, 2018: MabVax Therapeutics Announces Positive Interim Data from Expanded Cohort in Phase 1 Trial Evaluating MVT-5873 in Combination with First-Line Chemotherapy in Pancreatic Cancer 39
Feb 07, 2018: MabVax to Present Clinical Update on MVT-5873 at BIO CEO & Investor Conference 40
Feb 07, 2018: MabVax to Present Clinical Update on MVT-1075 (human antibody-based radioimmunotherapy)at BIO CEO & Investor Conference 40
Clinical Trial Profile Snapshots 41
Appendix 1457
Abbreviations 1457
Definitions 1457
Research Methodology 1458
Secondary Research 1458
About GlobalData 1459
Contact Us 1459
Disclaimer 1459
Source 1460

List of Tables
Pancreatic Cancer Therapeutics, Global, Clinical Trials by Region, 2018* 7
Pancreatic Cancer Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2018* 8
Pancreatic Cancer Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2018* 9
Pancreatic Cancer Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2018* 10
Pancreatic Cancer Therapeutics Clinical Trials, Europe, Top Five Countries, 2018* 11
Pancreatic Cancer Therapeutics Clinical Trials, North America, Top Countries, 2018* 12
Pancreatic Cancer Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries, 2018* 13
Pancreatic Cancer Therapeutics Clinical Trials, Central and South America, Top Five Countries, 2018* 14
Proportion of Pancreatic Cancer to Oncology Clinical Trials, G7 Countries (%), 2018* 15
Pancreatic Cancer Therapeutics, G7 Countries, Clinical Trials by Phase, 2018* 16
Pancreatic Cancer Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2018* 17
Proportion of Pancreatic Cancer to Oncology Clinical Trials, E7 Countries (%), 2018* 18
Pancreatic Cancer Therapeutics, E7 Countries, Clinical Trials by Phase, 2018* 19
Pancreatic Cancer Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2018* 20
Pancreatic Cancer Therapeutics, Global, Clinical Trials by Phase, 2018* 21
Pancreatic Cancer Therapeutics, Global, Clinical Trials In Progress by Phase 2018* 22
Pancreatic Cancer Therapeutics, Global, Clinical Trials by Trial Status, 2018* 23
Pancreatic Cancer Therapeutics Clinical Trials, Global, by End Point Status, 2018* 24
Pancreatic Cancer Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2013-2017 25
Pancreatic Cancer Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2018* 26
Pancreatic Cancer Therapeutics Clinical Trials, Global, Key Sponsors, 2018* 27
Pancreatic Cancer Therapeutics Clinical Trials, Global, Top Companies by Phase, 2018* 28
Pancreatic Cancer Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2018* 29

List of Figures
Pancreatic Cancer Therapeutics, Global, Clinical Trials by Region (%), 2018* 7
Pancreatic Cancer Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2018* 8
Pancreatic Cancer Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2018* 9
Pancreatic Cancer Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2018* 10
Pancreatic Cancer Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2018* 11
Pancreatic Cancer Therapeutics Clinical Trials, North America, Top Countries (%), 2018* 12
Pancreatic Cancer Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries (%), 2018* 13
Pancreatic Cancer Therapeutics Clinical Trials, Central and South America, Top Five Countries (%), 2018* 14
Proportion of Pancreatic Cancer to Oncology Clinical Trials, G7 Countries (%), 2018* 15
Pancreatic Cancer Therapeutics, G7 Countries, Clinical Trials by Phase, 2018* 16
Pancreatic Cancer Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2018* 17
Proportion of Pancreatic Cancer to Oncology Clinical Trials, E7 Countries (%), 2018* 18
Pancreatic Cancer Therapeutics, E7 Countries, Clinical Trials by Phase, 2018* 19
Pancreatic Cancer Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2018* 20
Pancreatic Cancer Therapeutics, Global, Clinical Trials by Phase (%), 2018* 21
Pancreatic Cancer Therapeutics, Global, Clinical Trials In Progress by Phase, 2018* 22
Pancreatic Cancer Therapeutics, Global, Clinical Trials by Trial Status, 2018* 23
Pancreatic Cancer Therapeutics Clinical Trials, Global, by End Point Status, 2018* 24
Pancreatic Cancer Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2013-2017 25
Pancreatic Cancer Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2018* 26
Pancreatic Cancer Therapeutics Clinical Trials, Global, Key Sponsors, 2018* 27
Pancreatic Cancer Therapeutics Clinical Trials, Global, Top Companies by Phase, 2018* 28
Pancreatic Cancer Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2018* 29
GlobalData Methodology 1458

Filed in: Pharmaceutical

Publisher : GlobalData

Name:
Email:
Phone:
Subject:
Comments:

More Reports

Title	Price	Buy Now
Ambulatory EHR Market by Delivery Mode (Cloud-based, On-premise), Application (e-Prescribing, PHM, Health Analytics, Practice, Patient & Referral Management), Practice Size (Large, Small-to-Medium, Solo), End User (Independent) – Global Forecast to 2027 “The ambulatory EHR market is projected to grow at a CAGR of 6.1% between 2022 and 2027.” The global ambulatory EHR market is projected to reach USD 5.7 billion in 2022 to USD 7.7 billion by 2027, at a CAGR of 6.1%during the forecast period. Growth in this market is driven by the opportunities provided by the market such as increasing demand for cloud-based ambulatory EHR market, and shift towards patient-centric healthcare delivery. However, the interoperability issues & data security concerns are some of the challenges that are expected to limit the growth of the market to a certain extent during the forecast period. “Cloud-based was the fastest-growing segment in the delivery mode of ambulatory EHR market in 2021” Cloud-based segment is projected to growth at the hi......	$4950
Pharmaceutical Excipients Market by Product (Organic Chemicals (Carbohydrates), Inorganic Chemicals (Calcium Phosphate)), Functionality (Fillers, Binders, Lubricants, Preservatives), Formulation (Tablets, Capsules, Parenteral) – Global Forecast to 2027 “The pharmaceutical excipients market growth can be attributed to factors such as the rising pharmaceuticals market, advancements in functional excipients, and the growing generics market. The rapidly growing biopharmaceuticals sector will also influence market growth..” The pharmaceutical excipients market is projected to reach USD 11.5 Billion by 2027 from USD 8.6 Billion in 2022, at a CAGR of 5.9% during the forecast period.The growth can be attributed to the expanding pharmaceutical industry which has fueled the drug production thereby increasing consumption rate for excipients. Additionally, factors like functional excipients development and upsurge in generics market is also likely to propel market growth. “The fillers & diluents functionality accounted for the larges......	$
Digital Pharmacy Market by Drug (Rx, OTC), Product (Medicine, Personal Care, Vitamins & Supplements, Diabetes, CVD, Oncology), Platform (Apps, Websites), Business Model (Captive, Franchise, Aggregator), Geographic (Urban, Rural) – Global Forecasts to 2027 “Digital Pharmacy market to register a CAGR of 17.0% during the forecasts period The digital pharmacy market is expected to reach USD 211.9 billion by 2027 from USD 96.5 billion in 2022, at a CAGR of 17.0% during the forecast period. The growth of this market is driven by the growing consumer preference toward buying online medicines during and post COVID-19 pandemic, consolidation in the market and partnerships, and increasing geriatric population. However, patients relying on pharmacists for clinical support and increasing number of illegal pharmacies are expected to restrain the growth of this market during the forecast period. “Over-the-counter (OTC) products segment is estimated to grow at the highest rate during the forecast period” On the basis ofdrug type, t......	$4950
Pharmacy Automation Market by Product (Automated Medication Dispensing & Storage Systems, Table-Top Counters, Retrieval Systems, Medication Compounding), End User (Inpatient, Outpatient (Fast-Track Clinics), Retail Pharmacies) – Global Forecast to 2027 The pharmacy automation market is expected to grow at a CAGR of 7.9% in the forecast period. The pharmacy automation market is projected to reach USD 8.2 billion by 2027 from USD 5.6 billion in 2022, at a CAGR of 7.9% during the forecast period. The growth in this market is attributed to the growing need to minimize medication errors, rapid decentralization of pharmacies, and growing focus on automation to reduce labor costs. However, the stringent regulations that delay product launches can inhibit the growth of this market. Based on product, the automated medication dispensing and storage systems segment holds the largest market share in 2021 Based on products, the pharmacy automation market is segmented into automated medication dispensing and storage systems, automated packagi......	$4950
Topical Drug Delivery Market by Type (Semi-solids (Creams, Gels, Lotions), Solids(Suppositories), Liquids(Solutions), Transdermal products), Route(Dermal, Ophthalmic), Facility of Use (Homecare setting, Hospitals, Burn Centres) – Global Forecast to 2027 The topical drug delivery market is expected to grow at a CAGR of 8.9% in the forecast period. The global topical drug delivery market is projected to reach USD 317.8 billion by 2027 from USD 207.4 billion in 2022, at a CAGR of 8.9%. The growth of this market can largely be attributed to the high prevalence of topical prescription therapy for dry eye diseases, growing focus of pharmaceutical companies on the R&D of smart transdermal drug delivery systems, increase in prevalence of central nervous disorders, rising preference for non-invasive drug delivery methods. “The semi-solid formulation segment accounted for the largest share of the topical drug delivery market, based on product in 2021.” Based on products, the topical drug delivery the market is segmented into ......	$4950
Cognition and Memory Enhancement Market by Product & Service (Cognition & Memory-enhancing Drugs, Brain-boosting Nutraceuticals, Cognitive Assessment & Training Solutions), Region (North America, Europe, Asia Pacific, ROW) – Global Forecast to 2026 “Increasing incidence and prevalence of neurological disorders is a key factors driving growth in the cognition and memory enhancement market’’ The global cognition and memory enhancement market is projected to reach USD 38.9 billion by 2026 from USD 23.4 billion in 2021, at a CAGR of 10.7% during the forecast period. Elevating prevalence of neurological disorders, such as dementia, epilepsy, Parkinson’s disease, Huntington’s disease, headache disorders, multiple sclerosis, neuroinfections, stroke, and cerebral palsy, have increased significantly over the years. “By product & service segment, the cognition & memory-enhancing drugs segment has registered fastest growth rate during the forecast period” Based on product & service, the cognition and memory en......	$4950
High Potency APIs/HPAPI Market by Type (Innovative, Generic), Type of Synthesis (Synthetic, Biotech, Biosimilars, mAbs, Vaccines), Manufacturers (Captive, Merchant), Application (Oncology, Hormonal Imbalance, Glaucoma) Region – Global forecast to 2027 The HPAPI market is projected to reach USD 39.6 Billion by 2027 from USD 24.5 billion in 2022, at a CAGR of 10.1% from 2022 to 2027. The market is driven by increasing demand for oncology drugs, growing demand for antibody-drug conjugates and others. “The innovative HPAPIs segment is expected to account for the largest share of the market in 2021” Based on type, the HPAPI market is segmented into innovative and generic. The innovative segment is expected to account for the largest share of the HPAPI market in 2021. The large share can be attributed to the increased R&D investments. “The Synthetic APIs segment to account for the largest share of the market in 2021” Based on type of synthesis, the market is segmented into synthetic and biotech HPAPIs. The synthetic AP......	$4950
Plasma Fractionation Market by Product (Immunoglobulins, Albumin, Protease Inhibitors, von Willebrand Factor, PCC), Application (Neurology, Immunology, Hematology, Rheumatology), End User (Clinical Research, Hospitals & Clinics) – Global Forecast to 2027 “Increased risk of communicable diseases, Rising prevalence of bleeding disorders in global population, Use of Immunoglobulin’s for a range of neurological conditions, including multiple sclerosis, neuropathic pain, and chronic fatigue syndrome is expected to drive the overall growth of the plasma fractionation market.” The global plasma fractionation market size is projected to reach USD 36.7 billion by 2027 from USD 26.5 billion in 2022, at a CAGR of 6.7% during the forecast period. Market growth is driven mainly by factors such as rapid growth of geriatric population, growing prevalence of respiratory disorders such as alpha-1-antitrypsin deficiency (AATD) and emphysema, and use of plasma fractionation products as first-line therapies for a number of bleeding, hematological, an......	$4950
Patient Engagement Solutions Market by Component (Software, Services), Delivery (On-Premise, Cloud), Therapy Area (CVD, Diabetes, Obesity, Fitness), Functionality (E-prescribing, Virtual care), End User (Provider, Payer, Patients) – Global Forecast to 2027 “Patient engagement solutions market to register a CAGR of 10.0% from 2022 to 2027” The patient engagement solutions market is projected to reach USD 27.9 billion by 2027 from USD 17.3 billion in 2022, at a CAGR of 10.0% during the forecast period. The growth of this market is driven by the adoption and changes in government regulations to promote patient-centric care and involve patients throughout the care journey, high demand for patient engagement solutions, and the growing utilization of m- health apps. However, interoperability issues for patient engagement solutions and a dreadth of skilled IT professionals in the healthcare industry are expected to restrain the growth of this market during the forecast period. “Services segment is expected to grow at the highest rate......	$4950
Healthcare Cloud Computing Market by Product (EMR/EHR, VNA, RIS, LIS, PIS), Deployment (Private Cloud, Hybrid Cloud, Public Cloud), Component (Software, Services), Pricing (Spot Pricing), Service (SaaS, IaaS, PaaS), End User – Global Forecasts to 2027 The global Healthcare cloud computing market is projected to reach USD 89.4 billion by 2027 from USD 39.4 billion in 2022, at a CAGR of 17.8%. The factors driving the market are adoption of technologies like telehealth, EHR, big data analytics, IoT, cloud computing, m health, wearlable devices, etc. “The healthcare provider solution was the largest segment in the healthcare cloud computing market in 2021.” The healthcare provider segment accounted for the larger share of 79.2% of the healthcare cloud computing market in 2021. The growing adoption of various health IT solutions such as EHR, e-prescribing, telehealth, mHealth, and others due to COVID-19 is one of the key factors contributing to the growth of this segment. “Among end users, the healthcare providers segment ac......	$4950

Pancreatic Cancer Global Clinical Trials Review, H1, 2018

Benefits of Sandler Research

User License for Reports

Reach Us

Contact Us

Knowledge Store

Email Subscription

our Feed Reader

Ambulatory EHR Market by Delivery Mode (Cloud-based, On-premise), Application (e-Prescribing, PHM, Health Analytics, Practice, Patient & Referral Management), Practice Size (Large, Small-to-Medium, Solo), End User (Independent) – Global Forecast to 2027

Pharmaceutical Excipients Market by Product (Organic Chemicals (Carbohydrates), Inorganic Chemicals (Calcium Phosphate)), Functionality (Fillers, Binders, Lubricants, Preservatives), Formulation (Tablets, Capsules, Parenteral) – Global Forecast to 2027

Digital Pharmacy Market by Drug (Rx, OTC), Product (Medicine, Personal Care, Vitamins & Supplements, Diabetes, CVD, Oncology), Platform (Apps, Websites), Business Model (Captive, Franchise, Aggregator), Geographic (Urban, Rural) – Global Forecasts to 2027

Pharmacy Automation Market by Product (Automated Medication Dispensing & Storage Systems, Table-Top Counters, Retrieval Systems, Medication Compounding), End User (Inpatient, Outpatient (Fast-Track Clinics), Retail Pharmacies) – Global Forecast to 2027

Topical Drug Delivery Market by Type (Semi-solids (Creams, Gels, Lotions), Solids(Suppositories), Liquids(Solutions), Transdermal products), Route(Dermal, Ophthalmic), Facility of Use (Homecare setting, Hospitals, Burn Centres) – Global Forecast to 2027

Cognition and Memory Enhancement Market by Product & Service (Cognition & Memory-enhancing Drugs, Brain-boosting Nutraceuticals, Cognitive Assessment & Training Solutions), Region (North America, Europe, Asia Pacific, ROW) – Global Forecast to 2026

High Potency APIs/HPAPI Market by Type (Innovative, Generic), Type of Synthesis (Synthetic, Biotech, Biosimilars, mAbs, Vaccines), Manufacturers (Captive, Merchant), Application (Oncology, Hormonal Imbalance, Glaucoma) Region – Global forecast to 2027

Plasma Fractionation Market by Product (Immunoglobulins, Albumin, Protease Inhibitors, von Willebrand Factor, PCC), Application (Neurology, Immunology, Hematology, Rheumatology), End User (Clinical Research, Hospitals & Clinics) – Global Forecast to 2027

Patient Engagement Solutions Market by Component (Software, Services), Delivery (On-Premise, Cloud), Therapy Area (CVD, Diabetes, Obesity, Fitness), Functionality (E-prescribing, Virtual care), End User (Provider, Payer, Patients) – Global Forecast to 2027

Healthcare Cloud Computing Market by Product (EMR/EHR, VNA, RIS, LIS, PIS), Deployment (Private Cloud, Hybrid Cloud, Public Cloud), Component (Software, Services), Pricing (Spot Pricing), Service (SaaS, IaaS, PaaS), End User – Global Forecasts to 2027